BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 99 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q1 2015. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2017 | $230,000 | -10.5% | 43,926 | -4.8% | 0.00% | 0.0% |
| Q2 2017 | $257,000 | -30.7% | 46,149 | +4.5% | 0.00% | 0.0% |
| Q1 2017 | $371,000 | +27.5% | 44,174 | -3.8% | 0.00% | 0.0% |
| Q4 2016 | $291,000 | +36.0% | 45,913 | -5.6% | 0.00% | 0.0% |
| Q3 2016 | $214,000 | +55.1% | 48,613 | 0.0% | 0.00% | 0.0% |
| Q2 2016 | $138,000 | -42.0% | 48,613 | -42.4% | 0.00% | 0.0% |
| Q1 2016 | $238,000 | -82.3% | 84,469 | -35.1% | 0.00% | -83.3% |
| Q4 2015 | $1,343,000 | -9.6% | 130,148 | -0.1% | 0.01% | -14.3% |
| Q3 2015 | $1,485,000 | +26.0% | 130,253 | +65.0% | 0.01% | +40.0% |
| Q2 2015 | $1,179,000 | +45.9% | 78,936 | -11.8% | 0.01% | +66.7% |
| Q1 2015 | $808,000 | +1.1% | 89,460 | +36.2% | 0.00% | 0.0% |
| Q4 2014 | $799,000 | +51.9% | 65,677 | +22.1% | 0.00% | +50.0% |
| Q3 2014 | $526,000 | -23.7% | 53,799 | -0.4% | 0.00% | -33.3% |
| Q2 2014 | $689,000 | +1926.5% | 54,005 | +144.5% | 0.00% | – |
| Q2 2013 | $34,000 | – | 22,090 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |